ACTRN12621001620819已完成未知
Feasibility and effectiveness of a six months period of virtual exercise program via zoom apps delivery method on the risk of fall, muscle strength, balance and quality of life among community-dwelling older adults aged 60 years and above from Kuching, Sarawak.
Janet Bong May Ing0 个研究点目标入组 52 人开始时间: 2021年11月26日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 60 Years 至 o limit（—）
- 性别
- All
入选标准
- •aged > 60 years and above from the local community
- •able to ambulate independently with or without a walking stick
- •those who have a falls risk.
- •those who have smartphone or device to connect to the internet.
排除标准
- •participants with acute or chronic conditions who are unable to complete an hour exercise program which includes severe musculoskeletal pain, cardiovascular diseases such as stroke with hemiplegia and unstable angina.
- •neurological diseases with progressive weakness.
- •postural hypotension, vestibular problem.
- •uncorrected visual issues.
- •cognitive deficits (Montreal Cognitive Assessment (MoCA) test score less than 20).
- •participating in another exercise program six weeks ago.
- •unable to read and understand Bahasa Malaysia or English.
研究者
相似试验
进行中（未招募）
不适用
Comparison of treatment of blood clots in the veins of the leg / pelvis as well as of blood clots in the lung of patients with active cancer. The treatments compared are Innohep® Treatment Versus Warfarin , an oral Vitamin K antagonist.EUCTR2009-018141-20-LVEO Pharma A/S900
进行中（未招募）
不适用
Comparison of treatment of blood clots in the veins of the leg / pelvis as well as of blood clots in the lung of patients with active cancer. The treatments compared are Innohep® Treatment Versus Warfarin , an oral Vit. K antagonist.EUCTR2009-018141-20-PTEO Pharma A/S900
进行中（未招募）
不适用
Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT - CATCHThromboembolism (VTE) in patients with active cancerMedDRA version: 12.1Level: LLTClassification code 10066899Term: Venous thromboembolismEUCTR2009-018141-20-GREO Pharma A/S900
进行中（未招募）
3 期
Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INTCTRI/2010/091/000598EO Pharma AS1,000
进行中（未招募）
不适用
Comparison of treatment of blood clots in the veins of the leg / pelvis as well as of blood clots in the lung of patients with active cancer. The treatments compared are Innohep® Treatment Versus Warfarin , an oral Vit. K antagonist.Thromboembolism (VTE) in patients with active cancerMedDRA version: 14.1Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 100000004866EUCTR2009-018141-20-DEEO Pharma A/S900